热门资讯> 正文
I-Mab的ADS售价为6500万美元
2025-08-01 20:13
- I-Mab (NASDAQ:IMAB) has priced a public offering of 33.3 million American Depositary Shares (ADSs) at $1.95 per ADS, raising about $65 million in gross proceeds.
- All shares are being sold by the company, and the offering is expected to close on August 5, 2025, pending usual conditions.
- I-Mab plans to use the funds—along with its current cash—to support ongoing clinical trials, including a Phase 2 study of givastomig, a bispecific antibody targeting Claudin 18.2 and 4-1BB, with results expected by late 2027. Proceeds will also go toward working capital and general corporate needs.
- Source: Press Release
More on I-Mab Biopharma
- I-Mab to buy Bridge Health to strengthen cancer drug development
- Seeking Alpha’s Quant Rating on I-Mab Biopharma
- Historical earnings data for I-Mab Biopharma
- Financial information for I-Mab Biopharma
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
